Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases - PubMed (original) (raw)

. 2007 Jun 15;67(12):5840-50.

doi: 10.1158/0008-5472.CAN-06-4615.

Suzanne Eccles, Paul A Clarke, Angela Hayes, Bernard Nutley, Sonia Alix, Alan Henley, Francesca Di-Stefano, Zahida Ahmad, Sandrine Guillard, Lynn M Bjerke, Lloyd Kelland, Melanie Valenti, Lisa Patterson, Sharon Gowan, Alexis de Haven Brandon, Masahiko Hayakawa, Hiroyuki Kaizawa, Tomonubu Koizumi, Takahide Ohishi, Sonal Patel, Nahid Saghir, Peter Parker, Mike Waterfield, Paul Workman

Affiliations

Free article

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases

Florence I Raynaud et al. Cancer Res. 2007.

Free article

Abstract

Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we detail the pharmacologic properties of a prototype of a new series of inhibitors of class I PI3K. PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (2 nmol/L), p110beta (3 nmol/L), p110delta (3 nmol/L), and p110gamma (15 nmol/L). PI103 also inhibited TORC1 by 83.9% at 0.5 micromol/L and exhibited an IC50 of 14 nmol/L against DNA-PK. A high degree of selectivity for the PI3K family was shown by the lack of activity of PI103 in a panel of 70 protein kinases. PI103 potently inhibited proliferation and invasion of a wide variety of human cancer cells in vitro and showed biomarker modulation consistent with inhibition of PI3K signaling. PI103 was extensively metabolized, but distributed rapidly to tissues and tumors. This resulted in tumor growth delay in eight different human cancer xenograft models with various PI3K pathway abnormalities. Decreased phosphorylation of AKT was observed in U87MG gliomas, consistent with drug levels achieved. We also showed inhibition of invasion in orthotopic breast and ovarian cancer xenograft models and obtained evidence that PI103 has antiangiogenic potential. Despite its rapid in vivo metabolism, PI103 is a valuable tool compound for exploring the biological function of class I PI3K and importantly represents a lead for further optimization of this novel class of targeted molecular cancer therapeutic.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources